NCT06445465 - Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 24, 2020

Primary Completion Date

November 26, 2024

Study Completion Date

November 26, 2024

Conditions

Alpha-SynucleinopathyParkinson's DiseaseDementia With Lewy BodiesMultisystem Atrophy

Interventions

DRUG

[18F]MNI-1216

\[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.

Trial Locations (1)

06510

Invicro, New Haven